Decitabine

Large B-Cell Lymphoma (LBCL)

Ruijin HospitalSmall moleculePhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 89/ 100

Competitive context

71 Active assets in the Large B-Cell Lymphoma (LBCL) cohort.

Asset / Sponsor	Phase	Rating
Axicabtagene Ciloleucel Zhejiang Cancer Hospital	Phase 4	BB
Cyclophosphamide M.D. Anderson Cancer Center	Phase 4	BB
Fludarabine M.D. Anderson Cancer Center	Phase 4	BB
ETOPOSIDE University of California, Davis	Phase 2/3	BB
Inno-206 Ruijin Hospital	Phase 3	BB

View all 50 →

Same molecule, other indications

Decitabine is also rated in:

disease related to hematopoietic stem cell transplantDormant

BBB

Indicative ·

72 / 100

acute myeloid leukemia with t(8;21)(q22;q22) translocationDormant

BB

Indicative ·

70 / 100

acute myeloid leukemiaDormant

BB

Indicative ·

70 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.